A model for 2019-nCoV infection with treatment

Amar Nath Chatterjee¹ and Fahad Al Basir^{*2}

¹Department of Mathematics, K.L.S. College, Nawada, Magadh University, Bodh Gaya, Bihar-805110, India

²Department of Mathematics, Asansol Girls' College, Asansol-4, West Bebgal-713304, India

July 6, 2020

Abstract

The current emergence of coronavirus (2019-nCoV or SARS-CoV-2) puts the world in threat. The structural research on the receptor recognition by SARS-CoV-2 has identified the key interactions between SARS-CoV-2 spike protein and its host (epithelium cell) receptor, also known as *angiotensin-converting enzyme 2 (ACE2)*. It controls both the cross-species and human-to-human transmissions of SARS-CoV-2. In view of this, we propose and analyze a mathematical model for investigating the effect of CTL responses over the viral mutation to control the viral infection when a post-infection immunostimulant drug (Pidotimode) is administered at regular intervals. Dynamics of the system with and without impulses have been analyzed using the basic reproduction number. This study shows that proper dosing interval and drug dose both are important to eradicate the viral infection.

Keywords: Mathematical model; Basic reproduction number; Stability analysis; Immunostimulant drug; Angiotensin Converting Enzyme 2 (ACE2); Impulsive differential equation.

1 Introduction

¹ A novel coronavirus named 2019-nCoV or SARS-CoV-2 (an interim name

² proposed by WHO (World Health Organization) become pandemic since

^{*}Corresponding author. Email: fahadalbasir@yahoo.com

³ December 2019. The first infectious respiratory syndrome was recognised in ⁴ Wuhan, Hubei province of China. Dedicated virologist identified and recog-⁵ nised the virus within a short time [3]. The SARS-CoV-2 is a single standard ⁶ RNA virus genome which is closely related to severe acute respiratory syn-⁷ drome SARS-CoV [4]. The infection of SARS-CoV-2 is associated with a ⁸ SARS-CoV like a disease with a fatality rate of 3.4% [5]. The World Health ⁹ Organisation (WHO) have named the disease as COVID-19 and declared it ¹⁰ as a public health emergency worldwide [2].

The common symptoms of COVID-19 are fever, fatigue, dry cough, myal-11 gia. Also, some patients suffer from headaches, abdominal pain, diarrhea, 12 nausea, and vomiting. In the acute phase of infection, the disease may lead 13 to respiratory failure which leads to death also. From clinical observation, 14 within 1-2 days after patient symptoms, the patient becomes morbid after 15 4-6 days and the infection may clear within 18 days [6] depending on the 16 immune system. Thus appropriate quarantine measure for minimum two 17 weeks is taken by the public health authorities for inhibiting community 18 spread [1]. 19

In [3], Zhou *et al.* identified that the respiratory tract as principal in-20 fection site for COVID-19 infection. SARS-CoV-2 infects primary human 21 airway epithelial cells. Angiotensic converting enzyme II (ACE2) receptor 22 of epithelial cells plays an important role in cellular entry [3,8]. It has been 23 observed that ACE2 could be expressed in the oral cavity. ACE2 receptors 24 are higher in tongue than buccal and gingival tissues. These findings imply 25 that the mucosa of the oral cavity may be a potentially high-risk route of 26 COVID-19 infection. Thus epithelial cells of the tongue are the major routes 27 of entry for COVID-19. Zhou et al. [3] also reported that SARS-CoV-2 spikes 28 S bind with ACE2 receptor of epithelial cells with high affinity. The bonding 29 between S - spike of SARS-CoV-2 with ACE2 [8], results from the fusion 30 between the viral envelope and the target cell membrane and the epithelial 31 cells become infected. The S protein plays a major role in the induction of 32 protective immunity during the infection of SARS-CoV-2 by eliciting neu-33 tralization antibody and T cell responses [10]. S protein is not only capable 34 of neutralizing antibody but it also contains several immunogenic T cell epi-35 topes. Some of the epitopes found in either S1 or S2 domain. These proteins 36 are useful for SARS-CoV-2 drug development [14]. 37

We know that virus clearance after acute infection is associated with strong antibody responses. Antibody responses have the potential to control the infection [15]. Also, CTL responses help to resolve infection and virus persistence caused by weak CTL responses [9]. Antibody responses against SARS-CoV-2 play an important role in preventing the viral entry process

[10]. Hsuch et al. [4] found that antibodies block viral entry by binding to the 43 S glycoprotein of SARS-CoV-2. To fight against the pathogen SARS-CoV-2, 44 the body requires SARS-CoV-2 specific $CD4^+T$ helper cells for developing 45 this specific antibody [10]. Antibody-mediated immunity protection helps 46 the anti-SARS-CoV serum to neutralize COVID-19 infection. Besides that, 47 the role of T cell responses in COVID-19 infection is very much important. 48 Cytotoxic T lymphocytes (CTLs) responses are important for recognizing 49 and killing infected cells, particularly in the lungs [10]. But the kinetic of 50 the CTL responses and antibody responses during SARS-CoV-2 infection is 51 yet to be explored. Our study will focus on the role of CTL and its possible 52 implication on treatment and drug development. the drug that stimulates 53 the CTL responses represents the best hope for control of COVID-19. Here 54 we have modeled the situation where CTLs can effectively control the viral 55 infection when the post-infection drug is administered at regular intervals. 56 Mathematical modeling with real data can help in predicting the dynam-57

ics and control of an infectious disease [32,33]. A four-dimensional dynamical
model for a viral infection is proposed by Tang et al. [11] for MERS-CoV
mediated by DPP4 receptors. In case of SARS-CoV-2, the infection process is almost similar with MERS-CoV and SARS-CoV. For SARS-CoV-2
infection, the ACE2 receptor of epithelium cell are the major target area.

Since the dynamics of the disease transmission of SARS-CoV-2 in cellular level is yet to be explored, thus we investigate the system in the light of previous literature of [11,26–29] to formulate the dynamic model which play a significant role in describing the interaction between uninfected cells, free virus and CTL responses. We propose a novel deterministic model which describes the cell biological infection of SARS-CoV-2 with epithelial cells and the role of the ACE2 receptor.

We explained the dynamics in the acute infection stage. It has been observed that CTL proliferate and differentiate antibody production after they encounter antigen. Here we investigate the effect of CTL responses over the viral mutation to control viral infection when a post-infection drug a is administered at regular intervals by mathematical perspective.

It is clinically evident that immunostimulants play a crucial role in the case of respiratory disease. Among the currently available immunostimulants, Pidotimod is the most effective for the respiratory disease [31]. Pidotimod increases the level of immunoglobulins (IgA, IgM, IgG) and activates the CTL responses to fight against the disease.

In this article, we have considered the infection dynamics of SARS-CoV-2 infection in the acute stage. We have used impulsive differential equations to study the immunostimulant drug dynamics and the effects of perfect

drug adherence. In recent years the effects of perfect adherence have been studied by using impulsive differential equations in [12, 13, 17–21]. With the help of impulsive differential equations, the effect of maximal acceptable drug holidays and optimal dosage can be found more precisely [12, 21].

The article is organised as follows: The very next section contains the formulation of the impulsive mathematical model. Dynamics of the system without impulses has been provided in section 3. The system with impulses has been analysed in section 4. Numerical simulations, on the basis of the outcomes of section 3 and 4, have been included in section 5. Discussion in section 6 concludes the paper.

2 Model formulation

As discussed in the previous section, we propose a model considering the interaction between epithelium cells and SARS-CoV-2 virus along with lytic CTL responses over the infected cells. We consider five populations namely the uninfected epithelium cells T(t), infected cells I(t), ACE2 receptor of the epithelial cells E(t) and CTLs against the pathogen C(t).

⁹⁹ IIn this model, we consider which represents the concentration of ACE2 ¹⁰⁰ on the surface of uninfected cells, which can be recognized by surface spike ¹⁰¹ (S) protein of SARS-CoV-2 [24].

It is assumed that the susceptible cells are produced at a rate λ_1 from the precursor cells and die at a rate d_T . The susceptible cells become infected a rate $\beta E(t)V(t)T(t)$. The constant d_I is the death rate of the infected cells. Infected cells are also cleared by the body's defensive CTLs at a rate p.

The infected cells produce new viruses at the rate md_I during their life, and d_V is the death rate of new virions, where m is any positive integer. It is also assumed that ACE2 is produced from the surface of uninfected cells at the constant rate λ_2 and the ACE2 is destroyed, when free viruses try to infect uninfected cells, at the rate $\theta\beta E(t)V(t)T(t)$ and is hydrolyzed at the rate $d_E E$.

 112 CTL proliferation in the presence of infected cells is described by the term

$$\alpha IC\left(1-\frac{C}{C_{max}}\right),\,$$

which shows the antigen dependent proliferation. Here we consider the logistic growth of CTL with C_{max} as the maximum concentration of CTL and d_c is its rate of decay.

¹¹⁷ With the above assumptions, we have the following mathematical model ¹¹⁸ characterising the SARS-CoV-2 dynamics:

$$\frac{dT}{dt} = \lambda_1 - \beta EVT - d_T T,$$

$$\frac{dI}{dt} = \beta EVT - d_I I - pIC,$$

$$\frac{dV}{dt} = md_I I - d_V V,$$

$$\frac{dE}{dt} = \lambda_2 - \theta \beta EVT - d_E E,$$

$$\frac{dC}{dt} = \alpha YC \left(1 - \frac{C}{C_{max}}\right) - d_c C.$$
(1)

We now modify the above model incorporating pulse periodic drug dosing using impulsive differential equation [22, 23].

We consider the perfect adherence behaviour of immunostimulant drug for SARS-CoV-2 infected patients at fixed drug dosing times $t_k, k \in \mathbb{N}$.

¹²³ We assume that CTL cells increases by a fixed amount ω , which is pro-¹²⁴ portional to the total number of CTLs that the drug can stimulate. Thus ¹²⁵ the above model takes the following form:

$$\frac{dT}{dt} = \lambda_1 - \beta EVT - d_T T,$$

$$\frac{dI}{dt} = \beta EVT - d_I I - pIC,$$

$$\frac{dV}{dt} = md_I I - d_V V,$$

$$\frac{dE}{dt} = \lambda_2 - \theta \beta EVT - d_E E,$$

$$\frac{dC}{dt} = \alpha YC \left(1 - \frac{C}{C_{max}}\right) - d_c C, \qquad t \neq t_k,$$

$$C(t_k^+) = \omega + C(t_k^-), \qquad t = t_k.$$
(2)

Here, $C(t_k^-)$ denotes the CTL cells concentration immediately before the impulse, $C(t_k^+)$ denotes the concentration after the impulse and ω is the fixed amount which is proportional to the total number of CTLs the drug stimulates at each impulse time $t_k, k \in \mathbb{N}$.

Remark 1. It can be noted that when there is no drug application in the system, model (2) becomes model (1).

¹³² 3 Analysis of the system without drug

In this section, we analyse the dynamics of the system without impulses i.e.
system (1). We have derived the *basic reproduction number* for the system.
Stability of equilibria are discussed using the number.

¹³⁶ 3.1 Existence of equilibria

¹³⁷ Model (2) has three steady states namely (i) the disease-free equilibrium ¹³⁸ $E_1\left(\frac{\lambda_1}{d_T}, 0, 0, \frac{\lambda_2}{d_E}, 0\right)$, (ii) with $\bar{E} > \frac{d_T d_V}{\beta \lambda_1 m}$, there is a CTL-responses-free equi-¹³⁹ librium, $E_2(\bar{T}, \bar{I}, \bar{V}, \bar{E}, 0)$, where,

$$\bar{T} = \frac{d_V}{\beta m \bar{E}}, \quad \bar{I} = \frac{\beta \lambda_1 n E - d_T d_V}{\beta d_I m \bar{E}}, \quad \bar{V} = \frac{\beta \lambda_1 m E - d_T d_V}{\beta d_V \bar{E}},$$

$$\bar{E} = \frac{-(\theta \beta \lambda_1 m - \beta \lambda_2 m) + \sqrt{(\theta \beta \lambda_1 m - \beta \lambda_2 m)^2 + 4\beta m d_T d_V d_E \theta}}{2\beta d_E m}$$

and (iii) the endemic equilibrium E^* which is given by

$$T^* = \frac{\lambda_1 \alpha - d_I \alpha I^* - p d_c}{d_T \alpha},$$

$$V^* = \frac{d_I m I^*}{d_V}, \quad E^* = \frac{\lambda_2 \alpha - \theta \alpha d_I I^* - \theta p d_c}{d_E \alpha},$$

$$C^* = \frac{(\alpha I^* - d_c) C_{max}}{\alpha I^*}.$$

¹⁴¹ where, I^* is the positive root of the cubic equation

$$L_0 I^3 + L_1 I^2 + L_2 I + L_3 = 0, (3)$$

142 with,

$$\begin{split} L_0 &= -\alpha^2 \theta \beta d_I^3 m, \\ L_1 &= -2\alpha \theta \beta d_I^2 d_c m p + \alpha^2 \theta \beta d_I^2 \lambda_1 m + \alpha^2 \beta d_I^2 \lambda_2 m, \\ L_2 &= \alpha^2 d_T d_I d_V d_E + \alpha \theta \beta d_I d_c \lambda_1 m p + \alpha \beta d_I d_c \lambda_2 m p \\ &- \alpha^2 \beta d_I \lambda_1 \lambda_2 m - \theta \beta d_I d_c^2 m p^2, \\ L_3 &= \alpha d_T d_V d_E d_c p. \end{split}$$

143 **Remark 2.** Note that $L_0 < 0$ and $L_3 > 0$. Thus, the equation (3) has at 144 least one positive real root. If $L_1 > 0$ and $L_2 < 0$, then (3) can have two 145 positive roots. For a feasible endemic equilibrium we also need

$$\min\left\{\frac{\lambda_1\alpha - pd_c}{d_I\alpha}, \frac{\lambda_2\alpha - \theta pd_c}{\theta\alpha d_I}\right\} > I^* > \frac{d_c}{\alpha}$$

¹⁴⁶ 3.2 Stability of equilibria

In this section, the characteristic equation at any equilibria is determined for the local stability of the system (2). Linearizing the system (2) at any equilibria E(T, I, V, E, C) yields the characteristic equation

$$\triangle(\xi) = \mid \xi I_n - \mathbf{A} \mid = 0,$$

where I_n is the identity matrix and $\mathbf{A} = [a_{ij}]$ is the following 5×5 matrix given by

$$\mathbf{A} = \begin{bmatrix} -\beta EV - d_T & 0 & -\beta ET & -\beta VT & 0\\ \beta EV & -d_I - pC & \beta ET & \beta VT & -pI\\ 0 & d_Im & -d_v & 0 & 0\\ -\theta \beta EV & 0 & -\theta \beta ET & -\theta \beta VT - d_E & 0\\ 0 & \alpha C(1 - \frac{C}{C_{max}}) & 0 & 0 & a_{55} \end{bmatrix},$$

with $a_{55} = \alpha I (1 - \frac{2C}{C_{max}}) - d_c$. We finally get the characteristic equation as

$$\psi(\xi) = \xi^5 + A_1 \xi^4 + A_2 \xi^3 + A_3 \xi^2 + A_4 \xi + A_5 = 0.$$
(4)

The coefficients A_i , i = 1, 2, ..., 5 are given in **Appendix-A**.

Looking at stability of any equilibrium E, the Routh-Hurwitz criterion gives that all roots of this characteristic equation (4) have negative real parts, provided the following conditions hold

$$A_5 > 0, \ A_1A_2 - A_3 > 0, \ A_3(A_1A_2 - A_3) - A_1(A_1A_4 - A_5) > 0, (A_1A_2 - A_3)(A_3A_4 - A_2A_5) - (A_1A_4 - A_5)^2 > 0.$$
(5)

157 Let us define the *basic reproduction number* as

$$R_0 = \frac{m\beta\lambda_1\lambda_2}{d_T d_E d_V},\tag{6}$$

then using (5) we can derived the following result:

Theorem 1. Disease-free equilibrium $E_1\left(\frac{\lambda_1}{d_T}, 0, 0, \frac{\lambda_2}{d_E}, 0\right)$ of the model (2) is stable for $R_0 < 1$, and unstable for $R_0 > 1$.

At E_2 one eigenvalue is $-d_c$ and rest of the eigenvalues satisfy the following equation

$$\xi^4 + B_1\xi^3 + B_2\xi^2 + B_3\xi + B_4 = 0$$

- The coefficients B_i , i = 1, 2, ..., 5 are given in **Appendix-B**.
- ¹⁶⁴ Using Routh-Hurwitz criterion, we have the following theorem.

Theorem 2. CTL-free equilibrium, $E_2(\bar{T}, \bar{I}, \bar{V}, \bar{E}, 0)$, is asymptotically stable if and only if the following conditions are satisfied

$$B_1 > 0, \quad B_2 > 0, \quad B_3 > 0, \quad B_4 > 0,$$

$$B_1 B_2 - B_3 > 0, \quad (B_1 B_2 - B_3) B_3 - B_1^2 B_4 > 0.$$
(7)

¹⁶⁷ Denoting $A_i^* = A_i(E^*)$ and using (5), we have the following theorem ¹⁶⁸ establishing the stability of coexisting equilibrium E^* .

Theorem 3. The coexisting equilibrium E^* is asymptotically stable if and only if the following conditions are satisfied

$$A_{5}^{*} > 0, \ A_{1}^{*}A_{2}^{*} - A_{3}^{*} > 0, \ A_{3}^{*}(A_{1}^{*}A_{2}^{*} - A_{3}^{*}) - A_{1}^{*}(A_{1}^{*}A_{4}^{*} - A_{5}^{*}) > 0, (A_{1}^{*}A_{2}^{*} - A_{3}^{*})(A_{3}^{*}A_{4}^{*} - A_{2}^{*}A_{5}^{*}) - (A_{1}^{*}A_{4}^{*} - A_{5}^{*})^{2} > 0.$$

$$(8)$$

171 4 Dynamics of the system with impulsive drug 172 dosing

173 In this section we consider the model system (2). Before analysing the 174 system, we first discuss the one dimensional impulse system as follows:

$$\frac{dC}{dt} = \alpha IC \left(1 - \frac{C}{C_{max}}\right) - d_c C, \quad t \neq t_k.$$

$$C(t_k^+) = \omega + C(t_k^-), \quad t = t_k. \quad (9)$$

¹⁷⁵ $C(t_k^-)$ denotes the CTL responses immediately before the impulse drug dos-¹⁷⁶ ing, $C(t_k^+)$ denotes the concentration after the impulse and ω is the dose ¹⁷⁷ that is taken at each impulse time $t_k, k \in \mathbb{N}$.

¹⁷⁸ We now consider the following linear system,

$$\frac{dC}{dt} = -d_c C, \qquad t \neq t_k
\Delta C = \omega, \qquad t = t_k$$
(10)

where, $\Delta = C(t_k^+) - C(t_k^-)$. Let $\tau = t_{k+1} - t_k$ be the period of the campaign. 179 The solution of the system (10) is, 180

$$C(t) = C(t_k^+)e^{-d_c(t-t_k)}, \quad \text{for } t_k < t \le t_{k+1}.$$
 (11)

In presence of impulsive dosing, we can get the recursion relation at the 181 moments of impulse as, 182

$$C(t_k^+) = C(t_k^-) + \omega.$$

Thus the amount of CTL before and after the impulse is obtained as,

$$C(t_k^+) = \frac{\omega(1 - e^{-k\tau d_c})}{1 - e^{-\tau d_c}}$$

and

$$C(t_{k+1}^{-}) = \frac{\omega(1 - e^{-k\tau d_c})e^{-\tau d_c}}{1 - e^{-\tau d_c}}.$$

Thus the limiting case of the CTL amount before and after one cycle is 183 as follows: 184

$$\lim_{k \to \infty} C(t_k^+) = \frac{\omega}{1 - e^{-\tau d_c}} \text{ and } \lim_{k \to \infty} C(t_{k+1}^-) = \frac{\omega e^{-\tau d_c}}{1 - e^{-\tau d_c}}$$

and 185

$$C(t_{k+1}^{+}) = \frac{\omega e^{-\tau d_c}}{1 - e^{-\tau d_c}} + \omega = \frac{\omega}{1 - e^{-\tau d_c}}.$$

Definition 1. Let $\Lambda \equiv (S_u, S_a, I, C), B_0 = [B : R^4_+ \to R_+],$ then we say 186 that B belong to class B_0 if the following conditions hold: 187

(i) B is continuous on
$$(t_k, t_{k+1}] \times R^3_+, n \in N$$
 and for all $\Lambda \in R^4$,

- $\lim_{(t,\mu)\to(t_k^+,\Lambda)} B(t,\mu) = B(t_k^+,\Lambda) \text{ exists,}$ (ii) B is locally Lipschitzian in Λ . 189
- 190

We now recall some results for our analysis from [22, 23]. 191

Lemma 1. Let Z(t) be a solution of the system (9) with $Z(0^+) \ge 0$. Then 192 $Z_i(t) \ge 0, i = 1, \dots, 4 \text{ for all } t \ge 0.$ Coreover, $Z_i(t) > 0, i = 1, \dots, 4 \text{ for all } t \ge 0.$ 193 t > 0 if $Z_i(0^+) > 0$, $i = 1, \dots, 4$. 194

Lemma 2. There exists a constant γ such that $T(t) \leq \gamma$, $I(t) \leq \gamma$, $V(t) \leq \gamma$ 195 $E(t) \leq \gamma$ and $C(t) \leq \gamma$ for each and every solution Z(t) of system (9) for 196 all sufficiently large t. 197

198 **Lemma 3.** Let $B \in B_0$ and also consider that

$$D^+B(t,Z) \le j(t,B(t,Z(t))), \quad t \ne t_k,$$

 $B(t,Z(t^+)) \le \Phi_n(B(t,Z(t))), \quad t = t_k,$

where $j : \mathbf{R}_{+} \times \mathbf{R}_{+} \to \mathbf{R}$ is continuous in $(t_{k}, t_{k+1}]$ for $e \in \mathbf{R}_{+}^{2}$, $n \in N$, the limit $\lim_{(t,V)\to(t_{k}^{+})} j(t,g) = j(t_{k}^{+},x)$ exists and $\Phi_{n}^{i}(i = 1,2) : \mathbf{R}_{+} \to \mathbf{R}_{+}$ is non-decreasing. Let y(t) be a maximal solution of the following impulsive differential equation

$$\frac{dx(t)}{dt} = j(t, x(t)), \quad t \neq t_k,$$

$$x(t^+) = \Phi_n(x(t)), \quad t = t_k, \quad x(0^+) = x_0,$$
(12)

existing on $(0^+, \infty)$. Then $B(0^+, Z_0) \leq x_0$ implies that $B(t, Z(t)) \leq y(t)$, $t \geq 0$, for any solution Z(t) of system (9). If j satisfies additional smoothness conditions to ensure the existence and uniqueness of solutions for (12), then y(t) is the unique solution of (12).

207 We now consider the following sub-system:

$$\frac{dC(t)}{dt} = -d_c C, \quad t \neq t_k, \quad C(t_k^+) = C(t_k) + \omega, \quad C(0^+) = C_0.$$
(13)

208

8 The Lemma provided above, gives the following result,

Lemma 4. System (13) has a unique positive periodic solution $\tilde{C}(t)$ with period τ and given by

$$\tilde{C}(t) = \frac{\omega \ exp(-d_c(t-t_k))}{1 - exp(-\tau d_c)}, \quad t_k \le t \le t_{k+1}, \quad \tilde{C}(0^+) = \frac{d_c}{1 - exp(-\tau d_c)}.$$

209 We use this result to derive the following theorem.

Theorem 4. The disease-free periodic orbit $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ of the system (2) is locally asymptotically stable if

$$\tilde{R_0} < 1 \tag{14}$$

212 where,

$$\tilde{R_0} = \frac{md_I\beta}{d_T d_E d_V \ \tau} \int_0^\tau \frac{\tilde{T}\tilde{E}}{d_I + p\tilde{C}} dt.$$

Proof. Let the solution of the system (9) without infected people be denoted by $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$, where

$$\tilde{C}(t) = \frac{\omega \exp(-d_c(t-t_k))}{1 - \exp(-\tau d_c)}, \quad t_k \le t \le t_{k+1},$$

with initial condition $C(0^+)$ as in Lemma 4. We now test the stability of the equilibria. The variational matrix at $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ is given by

$$M(t) = [m_{ij}] = \begin{pmatrix} -d_T & 0 & m_{13} & 0 & 0 \\ 0 & -(d_I + p\tilde{C}) & \beta \tilde{E}\tilde{T} & 0 & 0 \\ 0 & md_I & -d_v & 0 & 0 \\ 0 & 0 & m_{43} & -d_E & 0 \\ 0 & m_{52} & 0 & 0 & -d_c \end{pmatrix}$$

The monodromy matrix \mathbb{P} of the variational matrix M(t) is

$$\mathbb{P}(\tau) = I_n \exp\left(\int_0^\tau M(t)dt\right),\,$$

where I_n is the identity matrix. Note that m_{13}, m_{43}, m_{52} are not required for this analysis, therefore we have not mentioned their expressions.

We can write $\mathbb{P}(\tau) = \text{diag}(\sigma_1, \sigma_2, \sigma_3, \sigma_4, \sigma_5)$, where, σ_i , i = 1, 2, 3, 4, 5, are the Floquet multipliers and they are determined as

$$\sigma_1 = \exp\left(-d_T\tau\right), \quad \sigma_{2,3} = \exp\left(\int_0^\tau \frac{1}{2} \left[-A \pm \sqrt{A^2 - 4B}\right] dt\right),$$

$$\sigma_4 = \exp(-d_E\tau), \quad \sigma_5 = \exp(-d_c\tau).$$

Here $A = d_I + d_V + p\tilde{C}$ and $B = d_V(d_I + pC) - md_I\beta\tilde{E}\tilde{T}$. Clearly $\lambda_{1,4,5} < 1$. It is easy to check that $A^2 - 4B > 0$ and if $B \ge 0$ and hold then we have $\lambda_{2,3} < 1$. Thus, according to Floquet theory, the periodic solution $(\tilde{S}_u(t), 0, 0, \tilde{M}(t))$ of the system (9) is locally asymptotically stable if the conditions given in (14) hold.

Parameter	Explanation	Assigned value
λ_1	Production rate of uninfected cell	5
λ_2	Production rate of ACE2	1
β	Disease transmission rate	0.0001
heta	Bonding rate of ACE2	0.3
d_T	Death rate of uninfected cells	0.1
d_I	death rate of infected cells	0.1
d_V	Removal rate of virus	0.1
d_E	Hydrolysing rate of epithelium cells	0.1
d_C	decay rate of CTL	0.1
p	Killing rate of infected cells by CTL	0.01
m	Number of new virions produced	10-100
α	Proliferation rate of CTL	0.22
C_{max}	Maximum proliferation of CTL	100

Table 1: Set of parameter values used of numerical simulations.

²²² 5 Numerical results and discussion

In this section, we have observed the dynamical behaviours of system without drug (Figure 1 and Figure 2) and with impulsive effect of the drug dose (Figure 3 and Figure 4) through numerical simulations taking the parameters mainly from [11, 30, 31].

We have mainly focused on the role of CTL and its possible implication on the treatment and drug development. The drug that stimulates the CTL responses represents the best hope for control of COVID-19. Here we have determined the situation where CTLs can effectively control the viral infection when the post-infection drug is administered at regular intervals.

Existence of equilibria of the system without drug dose is shown for 232 different values of basic reproduction number R_0 . In plotting the Figure 1, 233 we have varied the value of infection rate β . It is observed that for lower 234 infection rate (that corresponds to $R_0 < 1$) disease free equilibrium E_1 is 235 stable (corroborated with Theorem 1). It becomes unstable and ensure the 236 existence of CTL-free equilibrium E_2 which is stable if $R_0 < 2.957$ (which 237 corresponds to $\beta = 0.00005963$) and unstable otherwise. (This satisfies 238 Theorem 2). Again we see that when E_2 is unstable the E^* is feasible. Also 239 whenever E^* exists, it is stable which verified the Theorem 3. 240

Effect of immune response rate α is plotted in Figure 2. We observe that in the absence of Drug, the CTL count and ACE2 increases with increasing value of α . Steady state value of infected cell I^* and virus V^* decreases



Figure 1: Existence and stability of equilibria is shown with respect to R_0 . Parameters values used in this figure are taken from Table 1 and m = 10. We have varied the value of β in (0.00001, 0.0001).



Figure 2: In the absence of the drug , effect of growth rate of CTL i.e. α on the steady state values of model population is shown. Parameters values used in this figure are same as Figure 1 except α .



Figure 3: Numerical solution of the model system with and without drug dose is shown taking parameters as in Figure 1. In this figure, $\tau = 2$, $\omega = 50$.

significantly as α increases.

Due to the impulsive nature of the drugs, there are no equilibria of the system i.e. population do not reach to towards equilibrium point, rather approach a periodic orbit. Hence, we evaluate equilibrium-like periodic orbits. There are two periodic orbits of the system (2) namely the disease-free periodic orbit and endemic periodic orbit. Here our aim is to find the stability of disease-free periodic orbit.

Figure 3 compare the system without and with impulse Drug effect. In 251 the absence of Drug we observe that the CTL count approaches a stable 252 equilibrium. Under regular drug dosing, the CTL count oscillates in an im-253 pulsive periodic orbit. Assuming perfect adherence, if the drug is sufficiently 254 strong, both infected cell and virus population are approaches towards ex-255 tinction. In this case, the total number of uninfected cells reach its maxi-256 mum level which implies that the system approaches towards its infection 257 free state (Theorem 4). 258

If we take sufficiently large impulsive interval $\tau = 5$ days (keeping rate $\omega = 50$ fixed, as in Figure 3) or lower dosage effect $\omega = 20$ (keeping interval $\tau = 2$ fixed, as in Figure 3), in both the cases, infection is remains present



Figure 4: Numerical solution of the model system for different rates of Drug dosing and different intervals of impulses.

in the system. Thus proper dosage of drug and optimal dosing interval areimportant for infection management.

²⁶⁴ 6 Conclusion

In this article, the role of immunostimulant drug (mainly Pidotimod) during 265 interactions between SARS-CoV-2 spike protein and epithelial cell receptor 266 ACE2 in COVID-19 infection has been studied as a possible drug dosing 267 policy. To reactivate the CTL responses during the acute infection period, 268 immune activator drugs is delivered to the host system in an impulsive mode. 269 The immunostimulant drug when administered, the best possible CTL 270 responses can act against the infected or virus-producing cells to neutralize 271 infection. This particular situation can keep the infected cell population at 272 a very low level. In the proposed mathematical model, we have analyzed 273 the optimal dosing regimen for which infection can be controlled. 274

From this study, it has been observed that when the basic reproduction ratio lies below one, we expect the system to attain its disease-free state. However, the system switches from disease-free state to CTL-free equilibrium state when $1 < R_0 < 2.957$. If $R_0 > 2.957$, the CTL-free equilibrium

²⁷⁹ moves to an endemic state (Figure 1).

Here we have explored the immunostimulant drug dynamics by the help 280 of impulsive differential equations. With the help of impulsive differential 281 equations, we have studied how the effect of maximal acceptable optimal 282 dosage can be found more precisely. Impulsive system shows that proper 283 dosage and dosing intervals are important for the eradication of the infected 284 cells and virus population which results the control of pandemic (Figure 3). 285 It has also been observed that the length of the dosing interval and the 286 drug dose play a very decisive role to control and eradicate the infection. 287 The most interesting prediction of this model is that effective therapy can 288 often be achieved, even for low adherence, if the dosing regimen is adjusted 289 appropriately (Figure 4). Also if the treatment regimen is not adjusted 290 properly, the therapy is not effective at all. This approach might also be 291 applicable to a combination of antiviral therapy. 292

Future extension work of the combination of drug therapy should also include more realistic patterns of non-adherence (random drug holidays, imperfect timing of successive doses), more accurate intracellular pharmacokinetics and leads towards better estimates of drug dosage and drug dosing intervals.

We end the paper with the quotation: "This outbreak is a test of political, financial and scientific solidarity for the world to fight a common enemy that does not respect borders..., what matters now is stopping the outbreak and saving lives." by Dr. Tedros, Director General, WHO [25].

302 Data Availability

³⁰³ The data used for supporting the findings are included within the article.

304 Conflict of interest

³⁰⁵ The authors declare that there is no conflict of interest.

306 Authors Contributions

307 Both authors contributed equally to this work.

308 **References**

- [1] World Health Organization, (2020). Considerations for quarantine
 of individuals in the context of containment for coronavirus disease
 (COVID-19): interim guidance, 29 February 2020.
- [2] World Health Organization, 2020. WHO Director-General's opening
 remarks at the media briefing on COVID-19-11 March 2020. Geneva,
 Switzerland.
- [3] Zhou, P. et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Published online February 3, 2020. https://doi.org/ 10.1038/s41586-020-2012-7.
- [4] Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang P.C. (2004). Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect, 10, 1062-1066.
- [5] Zhu, N. et al. (2020). A novel coronavirus from patients with pneumonia
 in China, N. Engl. J. Med. 382, 2019, 727-733.
- [6] Zou, L. et al. (2020). SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. Published online February
 19, 2020.
- [7] Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen
 Q., (2020). High expression of ACE2 receptor of 2019-nCoV on the
 epithelial cells of oral mucosa, International Journal of Oral Science,
 12:8.
- [8] Wan, Y., Shang, J., Graham, R., Baric, R.S. and Li, F., (2020). Receptor recognition by the novel coronavirus from Wuhan: an analysis
 based on decade-long structural studies of SARS coronavirus. Journal
 of virology, 94(7).
- [9] Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Tian, Z.
 (2020). Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & molecular immunology, 17(5), 533-535.
- [10] Hsueh-Ling Janice Oh, Samuel Ken-En Gan, Antonio Bertoletti, YeeJoo Tan, Understanding the T cell immune response in SARS coronavirus infection, Emerging Microbes and Infections (2012) 1, e23;
 doi:10.1038/emi.2012.26.

- [11] Tang S., Ma W., Bai P., (2017). A Novel Dynamic Model Describing the
 Spread of the MERS-CoV and the Expression of Dipeptidyl Peptidase
 4 Computational and Mathematical Methods in Medicine, Article ID
 5285810.
- ³⁴⁶ [12] Miron R.E., Smith R.J. (2010). Modelling imperfect adherence to HIV
 ³⁴⁷ induction therapy. BMC Infect Dis 10: 6.
- [13] Lou J, Smith RJ. Modelling the effects of adherence to the HIV fusion
 inhibitor enfuvirtide. J Theor Biol 2011; 268: 1–13.
- ³⁵⁰ [14] Li, G. and De Clercq, E., 2020. Therapeutic options for the 2019 novel ³⁵¹ coronavirus (2019-nCoV).
- [15] Rothan, H.A. and Byrareddy, S.N., 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity, p.102433.
- [16] Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X,
 Yu L, Dai X. Clinical study of mesenchymal stem cell treating acute
 respiratory distress syndrome induced by epidemic Influenza A (H7N9)
 infection, a hint for COVID-19 treatment. Engineering. 2020 Feb 28.
- [17] Smith RJ, Aggarwala BD. Can the viral reservoir of latently infected
 CD4(+) T cells be eradicated with antiretroviral HIV drugs? J Math
 Biol 2009; 59: 697-715.
- [18] Smith R.J. (2008). Explicitly accounting for antiretroviral drug uptake
 in theoretical HIV models predicts long-term failure of protease-only
 therapy. J Theor Biol 251, 227-237.
- [19] Smith R.J., Wahl LM. Drug resistance in an immunological model of
 HIV-1 infection with impulsive drug effects. Bull Math Biol 2005; 67:
 783-813.
- [20] Lou J., Chen L., Ruggeri T. (2009). An Impulsive Differential Model on
 Post Exposure Prophylaxis to HIV-1 Exposed Individual. J Biol Syst.
 17, 659–683.
- [21] Roy P. K., Chatterjee A. N., Li X. Z., (2016). The effect of vaccination
 to dendritic cell and immune cell interaction in HIV disease progression.
 International Journal of Biomathematics, 9 (1), p.1650005.

- Yu H., Zhong S., Agarwal R. P., (2011). Mathematics analysis and chaos
 in an ecological model with an impulsive control strategy, Communications in Nonlinear Science and Numerical Simulation, 16(2), 776-786.
- [23] Lakshmikantham V., Bainov D. D., Simeonov P. S., Theory of Impulsive
 Differential Equations, Series in Modern Applied Mathematics, World
 Scientific Publishing, 6, (1989).
- [24] Qing E., Gallagher T. (2020). SARS Coronavirus Redux. Trends in Immunology. Mar 12, 2020.
- ³⁸² [25] World Health Organization. Laboratory testing for coronavirus disease
 ³⁸³ 2019 (COVID-19) in suspected human cases: interim guidance, World
 ³⁸⁴ Health Organization, 2 March, 2020.
- [26] Nowak, M. A., May, R. M., (2000). Virus Dynamics: Mathematics
 Principles of Immunology and Virology,OxfordUniversity Press, London, UK.
- ³⁸⁸ [27] Perelson, A. S., Nelson, P. W., (1999) Mathematical analysis of HIV-1
 ³⁸⁹ dynamics in vivo, SIAM Review, vol. 41, no. 1, pp. 344.
- [28] Chatterjee, A. N., Saha, S., Roy, P. K., (2015), Human immunodeficiency virus/acquired immune deficiency syndrome: Using drug from mathematical perceptive, World J Virol, 4(4): 356-364.
- [29] Roy, P. K., Chatterjee, A. N., Greenhalgh, D., Khan, Q. J.A., (2013),
 Long Term Dynamics in a Mathematical Model of HIV-1 infection with
 delay in Different Variants of the basic drug the basic drug therapy,
 Nonlinear Analysis: Real WorldApplications, 14, pp.1621–1633.
- [30] Wu, C., Liu, Y., Yang, Y. et al. (2020). Analysis of therapeutic targets
 for SARS-CoV-2 and discovery of potential drugs by computational
 methods. Acta Pharmaceutica Sinica B.
- [31] Puggioni, F., Alves-Correia, M., Mohamed, M. F.et al. (2019). Immunostimulants in respiratory diseases: focus on Pidotimod. Multidisciplinary Respiratory Medicine, 14(1), 1–10.
- [32] Qureshi, S., Yusuf, A. Fractional derivatives applied to MSEIR problems: Comparative study with real world data. Eur. Phys. J. Plus 134,
 171 (2019). https://doi.org/10.1140/epjp/i2019-12661-7

[33] Sania Qureshi, Abdullahi Yusuf, Asif Ali Shaikh, Mustafa, Transmission
 dynamics of varicella zoster virus modeled by classical and novel frac-

tional operators using real statistical data, Physica A 534 (2019) 122149

409

410 Appendix-A

$$A_1 = -(a_{11} + a_{22} + a_{33} + a_{44} + a_{55}),$$

 $A_2 = a_{11}(a_{22} + a_{33}) + a_{23}a_{32} + a_{22}a_{33} - a_{14}a_{41} + (a_{11} + a_{22} + a_{33})a_{44}$ $-a_{25}a_{52} + (a_{11} + a_{22} + a_{33} + a_{44})a_{55},$

$$A_{3} = a_{32}(a_{11}a_{23} - a_{13}a_{21} - a_{24}a_{43}) - a_{11}a_{22}(a_{44} + a_{33}) + a_{14}a_{33}a_{41} + a_{44}(a_{23}a_{32} - a_{11}a_{33} - a_{22}a_{33}) + a_{25}a_{52}(a_{33} + a_{44} + a_{11}) - a_{11}a_{55}(a_{22} + a_{33}) + a_{23}a_{32}a_{55} - a_{22}a_{33}a_{55} - a_{44}a_{55}(a_{11} + a_{14}a_{41}a_{55} + a_{22} + a_{33}) + a_{14}a_{22}a_{41},$$

$$A_{5} = a_{25}a_{33}(a_{11}a_{44}a_{52} - a_{14}a_{41}a_{52}) + (a_{14}a_{21}a_{32} - a_{11}a_{24}a_{32})a_{43}a_{55} + a_{41}a_{55}(a_{13}a_{24}a_{32} - a_{14}a_{23}a_{32} + a_{14}a_{22}a_{33}) + a_{44}a_{55}(a_{11}a_{23}a_{32} - a_{13}a_{21}a_{32} - a_{11}a_{22}a_{33}).$$

411 Appendix-B

$$\begin{array}{rcl} B_1 &=& -(b_{11}+b_{22}+b_{33}+b_{44}), \\ B_2 &=& b_{11}b_{22}-b_{23}b_{32}+b_{33}(b_{11}+b_{22})-b_{14}b_{41} \\ && +b_{44}(b_{11}+b_{22}+b_{33}) \\ B_3 &=& b_{32}(b_{11}b_{23}-b_{13}b_{21})-b_{22}(b_{11}b_{33}-b_{14}b_{41}) \\ && +b_{14}b_{33}b_{41}-b_{24}b_{32}b_{43} \\ && +(b_{23}b_{32}-b_{11}b_{22})b_{44}-b_{33}b_{44}(b_{11}+b_{22}), \\ B_4 &=& b_{14}b_{41}(b_{23}b_{32}-b_{22}b_{33})-b_{13}b_{24}b_{32}b_{41} \\ && -b_{14}b_{21}b_{32}b_{43}+b_{32}(b_{11}b_{24}b_{43}+b_{13}b_{21}b_{44}) \\ && -b_{44}b_{11}(b_{23}b_{32}-b_{22}b_{33}). \end{array}$$